Company Provides Update on ALNPCSsc a Subcutaneously Administered RNAi Therapeutic Targeting PCSK9 Demonstrating up to 95 Knockdown of PCSK9 and up to 67 Reduction of Low Density Lipoprotein Cholesterol LDLC in NonHuman Primates...
↧